JP2015528447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528447A5 JP2015528447A5 JP2015528547A JP2015528547A JP2015528447A5 JP 2015528447 A5 JP2015528447 A5 JP 2015528447A5 JP 2015528547 A JP2015528547 A JP 2015528547A JP 2015528547 A JP2015528547 A JP 2015528547A JP 2015528447 A5 JP2015528447 A5 JP 2015528447A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- therapeutic agent
- condition
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 238000000034 method Methods 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692429P | 2012-08-23 | 2012-08-23 | |
| US61/692,429 | 2012-08-23 | ||
| PCT/US2013/055384 WO2014031487A1 (en) | 2012-08-23 | 2013-08-16 | Bivalent inhibitors of iap proteins and therapeutic methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528447A JP2015528447A (ja) | 2015-09-28 |
| JP2015528447A5 true JP2015528447A5 (enExample) | 2016-10-06 |
| JP6247298B2 JP6247298B2 (ja) | 2017-12-13 |
Family
ID=50148520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528547A Active JP6247298B2 (ja) | 2012-08-23 | 2013-08-16 | Ｉａｐタンパク質の二価阻害薬およびそれを用いた治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883771B2 (enExample) |
| EP (1) | EP2888265B1 (enExample) |
| JP (1) | JP6247298B2 (enExample) |
| KR (2) | KR102237888B1 (enExample) |
| CN (3) | CN109485662B (enExample) |
| AU (1) | AU2013306087B2 (enExample) |
| CA (1) | CA2882496C (enExample) |
| ES (1) | ES2654623T3 (enExample) |
| HK (1) | HK1211030A1 (enExample) |
| MX (1) | MX366130B (enExample) |
| RU (1) | RU2649975C2 (enExample) |
| WO (1) | WO2014031487A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US9969753B2 (en) * | 2014-04-16 | 2018-05-15 | Shenzhen Yongze Pharmaceutical Co., Ltd. | BCR-ABL diploid inhibitor, synthesizing method therefor, and uses thereof |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| AU2017253560B2 (en) | 2016-04-20 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| WO2017194390A1 (en) * | 2016-05-09 | 2017-11-16 | F. Hoffmann-La Roche Ag | Dimeric compounds |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB2567126A (en) * | 2017-06-23 | 2019-04-10 | Femtogenix Ltd | PBC compounds |
| CN107987083A (zh) | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
| CN112534055A (zh) | 2018-07-13 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 用于调节rtel1表达的寡核苷酸 |
| EP3829639A4 (en) * | 2018-07-31 | 2022-06-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule |
| WO2020027225A1 (ja) * | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| WO2021026349A1 (en) | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| PH12022550721A1 (en) | 2019-09-25 | 2024-05-13 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| WO2021098771A1 (en) * | 2019-11-19 | 2021-05-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment method with iap inhibitor |
| US20230029259A1 (en) * | 2019-12-02 | 2023-01-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents |
| TWI777321B (zh) * | 2019-12-04 | 2022-09-11 | 大陸商蘇州亞盛藥業有限公司 | 藥物組合及其用途 |
| EP4081217A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| EP4146218A4 (en) * | 2020-05-04 | 2024-08-28 | Ascentage Pharma (Suzhou) Co., Ltd. | METHODS OF TREATING CORONAVIRUS INFECTIONS |
| WO2022012671A1 (en) * | 2020-07-16 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | The crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof |
| WO2022179490A1 (en) * | 2021-02-23 | 2022-09-01 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical compositions and preparation methods thereof |
| CN117957018A (zh) | 2021-08-02 | 2024-04-30 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| TW202410919A (zh) | 2022-05-23 | 2024-03-16 | 美商英伊布里克斯公司 | Dr5促效劑與iap拮抗劑之組合療法 |
| US12508320B2 (en) | 2023-06-29 | 2025-12-30 | SeeCure Taiwan Co., Ltd. | Drug conjugate, pharmaceutical composition and method of treating hepatitis |
| WO2025090605A1 (en) * | 2023-10-24 | 2025-05-01 | University Of Houston System | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 |
| WO2025261398A1 (en) * | 2024-06-19 | 2025-12-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating diseases caused by hiv infection |
| CN119100970B (zh) * | 2024-08-30 | 2025-09-30 | 中国药科大学 | 基于热休克蛋白90的二价抑制剂及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| CN101128425B (zh) * | 2005-02-25 | 2012-12-26 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
| NZ572531A (en) * | 2006-05-05 | 2011-09-30 | Univ Michigan | Bivalent smac mimetics and the uses thereof |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| ES2643233T3 (es) * | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
-
2013
- 2013-08-16 CN CN201811229886.1A patent/CN109485662B/zh active Active
- 2013-08-16 CN CN201811229870.0A patent/CN109575049B/zh active Active
- 2013-08-16 WO PCT/US2013/055384 patent/WO2014031487A1/en not_active Ceased
- 2013-08-16 EP EP13831176.6A patent/EP2888265B1/en active Active
- 2013-08-16 MX MX2015002371A patent/MX366130B/es active IP Right Grant
- 2013-08-16 ES ES13831176.6T patent/ES2654623T3/es active Active
- 2013-08-16 KR KR1020207013450A patent/KR102237888B1/ko active Active
- 2013-08-16 JP JP2015528547A patent/JP6247298B2/ja active Active
- 2013-08-16 US US13/969,030 patent/US8883771B2/en active Active
- 2013-08-16 CN CN201380055219.5A patent/CN104718209A/zh active Pending
- 2013-08-16 RU RU2015107552A patent/RU2649975C2/ru active
- 2013-08-16 AU AU2013306087A patent/AU2013306087B2/en active Active
- 2013-08-16 HK HK15111880.3A patent/HK1211030A1/xx unknown
- 2013-08-16 CA CA2882496A patent/CA2882496C/en active Active
- 2013-08-16 KR KR1020157006767A patent/KR102111704B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528447A5 (enExample) | ||
| RU2015107552A (ru) | Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения | |
| JP2018533611A5 (enExample) | ||
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| JP2016508505A5 (enExample) | ||
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| PH12017501989B1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| RU2016141569A (ru) | Комбинации | |
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2016506916A5 (enExample) | ||
| RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP2016533366A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2015509536A5 (enExample) | ||
| JP2016528298A5 (enExample) | ||
| JP2015527401A5 (enExample) | ||
| JP2012041365A5 (enExample) | ||
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors |